temozolomide has been researched along with Microsatellite Instability in 6 studies
Microsatellite Instability: The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 9.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| "Over the past few years, the alkylating agent temozolomide has become the standard-of-care therapy for patients with glioblastoma, the most common brain tumor." | 7.75 | MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. ( Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S, 2009) |
| "To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia." | 5.12 | Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. ( Adamson, PC; Berg, SL; Blaney, SM; Delaney, SM; Dolan, ME; Hedge, M; Horton, TM; Ingle, AM; Thompson, PA; Weiss, HL; Wu, MF, 2007) |
| " In addition, microsatellite instability, leading to the putative mechanism of temozolomide (TMZ) resistance, was frequently detected." | 3.79 | Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics. ( Amano, T; Fujioka, Y; Hata, N; Iwaki, T; Mizoguchi, M; Murata, H; Nakamizo, A; Sasaki, T; Suzuki, SO; Yoshimoto, K, 2013) |
| "Over the past few years, the alkylating agent temozolomide has become the standard-of-care therapy for patients with glioblastoma, the most common brain tumor." | 3.75 | MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. ( Aldape, K; Cahill, DP; Iafrate, AJ; Louis, DN; Miao, J; Nutt, CL; Yip, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Raverot, G | 1 |
| Ilie, MD | 1 |
| Schwartz, C | 1 |
| Romagna, A | 1 |
| Machegger, L | 1 |
| Weiss, L | 1 |
| Huemer, F | 1 |
| Fastner, G | 1 |
| Kleindienst, W | 1 |
| Weis, S | 1 |
| Greil, R | 1 |
| Winkler, PA | 1 |
| Mizoguchi, M | 1 |
| Hata, N | 1 |
| Suzuki, SO | 1 |
| Fujioka, Y | 1 |
| Murata, H | 1 |
| Amano, T | 1 |
| Nakamizo, A | 1 |
| Yoshimoto, K | 1 |
| Iwaki, T | 1 |
| Sasaki, T | 1 |
| Yip, S | 1 |
| Miao, J | 1 |
| Cahill, DP | 1 |
| Iafrate, AJ | 1 |
| Aldape, K | 1 |
| Nutt, CL | 1 |
| Louis, DN | 1 |
| Pollack, IF | 1 |
| Hamilton, RL | 1 |
| Sobol, RW | 1 |
| Nikiforova, MN | 1 |
| Nikiforov, YE | 1 |
| Lyons-Weiler, MA | 1 |
| LaFramboise, WA | 1 |
| Burger, PC | 1 |
| Brat, DJ | 1 |
| Rosenblum, MK | 1 |
| Gilles, FH | 1 |
| Yates, AJ | 1 |
| Zhou, T | 1 |
| Cohen, KJ | 1 |
| Finlay, JL | 1 |
| Jakacki, RI | 1 |
| Horton, TM | 1 |
| Thompson, PA | 1 |
| Berg, SL | 1 |
| Adamson, PC | 1 |
| Ingle, AM | 1 |
| Dolan, ME | 1 |
| Delaney, SM | 1 |
| Hedge, M | 1 |
| Weiss, HL | 1 |
| Wu, MF | 1 |
| Blaney, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma[NCT00100802] | Phase 2 | 118 participants (Actual) | Interventional | 2005-03-21 | Completed | ||
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias[NCT00083070] | Phase 1 | 16 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of deaths due to complications of protocol therapy. (NCT00100802)
Timeframe: While receiving protocol therapy (up to 301 days excluding delays) or within 30 days of Termination of Protocol Therapy
| Intervention | patients (Number) |
|---|---|
| Surgery, Chemoradiotherapy, Rest, Maintenance, FUP | 1 |
Estimated one year survival using the Kaplan-Meier methodology. (NCT00100802)
Timeframe: One year
| Intervention | Estimated probability (Number) |
|---|---|
| Surgery, Chemoradiotherapy, Rest, Maintenance, FUP | 0.7208 |
1 review available for temozolomide and Microsatellite Instability
| Article | Year |
|---|---|
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors.
Topics: Biomarkers, Tumor; Humans; Immunotherapy; Microsatellite Instability; Mutation; Pituitary Neoplasms; | 2022 |
1 trial available for temozolomide and Microsatellite Instability
| Article | Year |
|---|---|
Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Dacarbazine; DNA Modi | 2007 |
4 other studies available for temozolomide and Microsatellite Instability
| Article | Year |
|---|---|
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunol | 2018 |
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; M | 2013 |
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival | 2009 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |
Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Child; Dacarbazine; DNA Mismatch Repair; Drug Resistance, Neoplas | 2010 |